A drug development company pioneering selective immunotherapies for autoimmune diseases with high unmet need.

GlycoEra is developing precision biologics for autoantibody driven inflammatory disorders that have the potential to serve as safer and more effective alternatives to existing standard of care. GlycoEra’s lead program is a biologic which rapidly and selectively depletes IgG4 from the blood stream to address IgG4-driven autoimmune disorders. Because other IgG antibodies are spared, deeper IgG4 depletion can be attained resulting in better efficacy without an increase in infection risk.